nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPRE—prostate gland—urinary bladder cancer	0.0415	0.103	CbGeAlD
Alendronate—PTPN4—prostate gland—urinary bladder cancer	0.0394	0.0978	CbGeAlD
Alendronate—PTPRS—prostate gland—urinary bladder cancer	0.0338	0.0838	CbGeAlD
Alendronate—PTPRE—female reproductive system—urinary bladder cancer	0.0226	0.0561	CbGeAlD
Alendronate—PTPN4—female reproductive system—urinary bladder cancer	0.0215	0.0534	CbGeAlD
Alendronate—PTPRE—vagina—urinary bladder cancer	0.0205	0.0507	CbGeAlD
Alendronate—ATP6V1A—prostate gland—urinary bladder cancer	0.0195	0.0483	CbGeAlD
Alendronate—PTPN4—vagina—urinary bladder cancer	0.0195	0.0483	CbGeAlD
Alendronate—PTPRS—female reproductive system—urinary bladder cancer	0.0184	0.0457	CbGeAlD
Alendronate—FDPS—prostate gland—urinary bladder cancer	0.0147	0.0364	CbGeAlD
Alendronate—ATP6V1A—renal system—urinary bladder cancer	0.0133	0.0329	CbGeAlD
Alendronate—PTPRE—lymph node—urinary bladder cancer	0.0132	0.0328	CbGeAlD
Alendronate—ATP6V1A—urethra—urinary bladder cancer	0.013	0.0323	CbGeAlD
Alendronate—PTPN4—lymph node—urinary bladder cancer	0.0126	0.0312	CbGeAlD
Alendronate—FDPS—seminal vesicle—urinary bladder cancer	0.0124	0.0308	CbGeAlD
Alendronate—PTPRS—lymph node—urinary bladder cancer	0.0108	0.0268	CbGeAlD
Alendronate—ATP6V1A—female reproductive system—urinary bladder cancer	0.0106	0.0264	CbGeAlD
Alendronate—FDPS—smooth muscle tissue—urinary bladder cancer	0.0104	0.0258	CbGeAlD
Alendronate—FDPS—renal system—urinary bladder cancer	0.01	0.0248	CbGeAlD
Alendronate—FDPS—urethra—urinary bladder cancer	0.00983	0.0244	CbGeAlD
Alendronate—ATP6V1A—vagina—urinary bladder cancer	0.00962	0.0239	CbGeAlD
Alendronate—FDPS—SREBP signalling—AMFR—urinary bladder cancer	0.0092	0.155	CbGpPWpGaD
Alendronate—FDPS—female reproductive system—urinary bladder cancer	0.00801	0.0199	CbGeAlD
Alendronate—FDPS—vagina—urinary bladder cancer	0.00725	0.018	CbGeAlD
Alendronate—ATP6V1A—lymph node—urinary bladder cancer	0.00622	0.0154	CbGeAlD
Alendronate—PTPRS—Extracellular matrix organization—LOXL4—urinary bladder cancer	0.00558	0.0939	CbGpPWpGaD
Alendronate—ATP6V1A—Transferrin endocytosis and recycling—TFRC—urinary bladder cancer	0.00526	0.0885	CbGpPWpGaD
Alendronate—FDPS—lymph node—urinary bladder cancer	0.00469	0.0116	CbGeAlD
Alendronate—PTPRS—Extracellular matrix organization—LOXL1—urinary bladder cancer	0.00423	0.0712	CbGpPWpGaD
Alendronate—Risedronate—PTGS2—urinary bladder cancer	0.00415	0.529	CrCbGaD
Alendronate—ATP6V1A—Iron uptake and transport—TFRC—urinary bladder cancer	0.00384	0.0646	CbGpPWpGaD
Alendronate—Clodronate—PTGS2—urinary bladder cancer	0.0037	0.471	CrCbGaD
Alendronate—PTPRE—IL6-mediated signaling events—MYC—urinary bladder cancer	0.00354	0.0596	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—TSC1—urinary bladder cancer	0.0017	0.0286	CbGpPWpGaD
Alendronate—FDPS—Activation of gene expression by SREBF (SREBP)—CREBBP—urinary bladder cancer	0.00152	0.0256	CbGpPWpGaD
Alendronate—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.00144	0.00272	CcSEcCtD
Alendronate—Alopecia—Gemcitabine—urinary bladder cancer	0.00143	0.00269	CcSEcCtD
Alendronate—Myalgia—Thiotepa—urinary bladder cancer	0.00142	0.00269	CcSEcCtD
Alendronate—Oesophagitis—Epirubicin—urinary bladder cancer	0.00141	0.00266	CcSEcCtD
Alendronate—Erythema—Gemcitabine—urinary bladder cancer	0.0014	0.00265	CcSEcCtD
Alendronate—Alopecia—Fluorouracil—urinary bladder cancer	0.0014	0.00265	CcSEcCtD
Alendronate—Melaena—Doxorubicin—urinary bladder cancer	0.00139	0.00263	CcSEcCtD
Alendronate—Influenza like illness—Doxorubicin—urinary bladder cancer	0.00138	0.00261	CcSEcCtD
Alendronate—Erythema—Fluorouracil—urinary bladder cancer	0.00138	0.00261	CcSEcCtD
Alendronate—Photosensitivity—Methotrexate—urinary bladder cancer	0.00136	0.00257	CcSEcCtD
Alendronate—Infection—Thiotepa—urinary bladder cancer	0.00135	0.00256	CcSEcCtD
Alendronate—Alopecia—Cisplatin—urinary bladder cancer	0.00133	0.00251	CcSEcCtD
Alendronate—Erythema—Cisplatin—urinary bladder cancer	0.00131	0.00247	CcSEcCtD
Alendronate—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.0013	0.00246	CcSEcCtD
Alendronate—Erythema multiforme—Etoposide—urinary bladder cancer	0.0013	0.00246	CcSEcCtD
Alendronate—Oesophagitis—Doxorubicin—urinary bladder cancer	0.0013	0.00246	CcSEcCtD
Alendronate—Anaemia—Gemcitabine—urinary bladder cancer	0.0013	0.00245	CcSEcCtD
Alendronate—Flatulence—Cisplatin—urinary bladder cancer	0.00129	0.00244	CcSEcCtD
Alendronate—Anaemia—Fluorouracil—urinary bladder cancer	0.00128	0.00241	CcSEcCtD
Alendronate—Photosensitivity—Epirubicin—urinary bladder cancer	0.00127	0.0024	CcSEcCtD
Alendronate—Malaise—Gemcitabine—urinary bladder cancer	0.00127	0.00239	CcSEcCtD
Alendronate—Muscle spasms—Cisplatin—urinary bladder cancer	0.00126	0.00238	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00124	0.00235	CcSEcCtD
Alendronate—Alopecia—Etoposide—urinary bladder cancer	0.00122	0.0023	CcSEcCtD
Alendronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—urinary bladder cancer	0.00122	0.0204	CbGpPWpGaD
Alendronate—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00121	0.00229	CcSEcCtD
Alendronate—Anaemia—Cisplatin—urinary bladder cancer	0.00121	0.00229	CcSEcCtD
Alendronate—Dyspepsia—Thiotepa—urinary bladder cancer	0.0012	0.00227	CcSEcCtD
Alendronate—Chest pain—Gemcitabine—urinary bladder cancer	0.0012	0.00226	CcSEcCtD
Alendronate—Myalgia—Gemcitabine—urinary bladder cancer	0.0012	0.00226	CcSEcCtD
Alendronate—Discomfort—Gemcitabine—urinary bladder cancer	0.00118	0.00223	CcSEcCtD
Alendronate—Malaise—Cisplatin—urinary bladder cancer	0.00118	0.00223	CcSEcCtD
Alendronate—Photosensitivity—Doxorubicin—urinary bladder cancer	0.00118	0.00222	CcSEcCtD
Alendronate—Chest pain—Fluorouracil—urinary bladder cancer	0.00118	0.00222	CcSEcCtD
Alendronate—Myalgia—Fluorouracil—urinary bladder cancer	0.00118	0.00222	CcSEcCtD
Alendronate—Dysgeusia—Etoposide—urinary bladder cancer	0.00117	0.00222	CcSEcCtD
Alendronate—Constipation—Thiotepa—urinary bladder cancer	0.00117	0.0022	CcSEcCtD
Alendronate—Pain—Thiotepa—urinary bladder cancer	0.00117	0.0022	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00116	0.0195	CbGpPWpGaD
Alendronate—Discomfort—Fluorouracil—urinary bladder cancer	0.00116	0.00219	CcSEcCtD
Alendronate—Muscle spasms—Etoposide—urinary bladder cancer	0.00115	0.00218	CcSEcCtD
Alendronate—Infection—Gemcitabine—urinary bladder cancer	0.00114	0.00215	CcSEcCtD
Alendronate—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00112	0.00212	CcSEcCtD
Alendronate—Infection—Fluorouracil—urinary bladder cancer	0.00112	0.00212	CcSEcCtD
Alendronate—Myalgia—Cisplatin—urinary bladder cancer	0.00111	0.00211	CcSEcCtD
Alendronate—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00111	0.00211	CcSEcCtD
Alendronate—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00111	0.0021	CcSEcCtD
Alendronate—Anaemia—Etoposide—urinary bladder cancer	0.00111	0.00209	CcSEcCtD
Alendronate—Discomfort—Cisplatin—urinary bladder cancer	0.0011	0.00208	CcSEcCtD
Alendronate—Urticaria—Thiotepa—urinary bladder cancer	0.00108	0.00205	CcSEcCtD
Alendronate—Malaise—Etoposide—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Alendronate—Vertigo—Etoposide—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Alendronate—Abdominal pain—Thiotepa—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Alendronate—Body temperature increased—Thiotepa—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00107	0.00203	CcSEcCtD
Alendronate—Infection—Cisplatin—urinary bladder cancer	0.00106	0.00201	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00104	0.00197	CcSEcCtD
Alendronate—Asthma—Methotrexate—urinary bladder cancer	0.00103	0.00195	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00103	0.00194	CcSEcCtD
Alendronate—FDPS—SREBP signalling—PPARG—urinary bladder cancer	0.00102	0.0172	CbGpPWpGaD
Alendronate—Dry skin—Epirubicin—urinary bladder cancer	0.00102	0.00193	CcSEcCtD
Alendronate—Chest pain—Etoposide—urinary bladder cancer	0.00102	0.00193	CcSEcCtD
Alendronate—Discomfort—Etoposide—urinary bladder cancer	0.00101	0.00191	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00101	0.0019	CcSEcCtD
Alendronate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.001	0.0019	CcSEcCtD
Alendronate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000992	0.00187	CcSEcCtD
Alendronate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000988	0.00187	CcSEcCtD
Alendronate—Gastritis—Epirubicin—urinary bladder cancer	0.000988	0.00187	CcSEcCtD
Alendronate—Pain—Gemcitabine—urinary bladder cancer	0.00098	0.00185	CcSEcCtD
Alendronate—Constipation—Gemcitabine—urinary bladder cancer	0.00098	0.00185	CcSEcCtD
Alendronate—Asthenia—Thiotepa—urinary bladder cancer	0.000978	0.00185	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000973	0.00184	CcSEcCtD
Alendronate—Infection—Etoposide—urinary bladder cancer	0.000972	0.00184	CcSEcCtD
Alendronate—Abdominal distension—Epirubicin—urinary bladder cancer	0.000971	0.00184	CcSEcCtD
Alendronate—Dysphagia—Epirubicin—urinary bladder cancer	0.000965	0.00182	CcSEcCtD
Alendronate—Asthma—Epirubicin—urinary bladder cancer	0.000965	0.00182	CcSEcCtD
Alendronate—Pruritus—Thiotepa—urinary bladder cancer	0.000964	0.00182	CcSEcCtD
Alendronate—Pain—Fluorouracil—urinary bladder cancer	0.000964	0.00182	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—FGFR3—urinary bladder cancer	0.000955	0.0161	CbGpPWpGaD
Alendronate—Dry skin—Doxorubicin—urinary bladder cancer	0.000947	0.00179	CcSEcCtD
Alendronate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000945	0.00178	CcSEcCtD
Alendronate—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000941	0.00178	CcSEcCtD
Alendronate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000932	0.00176	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00093	0.00176	CcSEcCtD
Alendronate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000929	0.00175	CcSEcCtD
Alendronate—Gastritis—Doxorubicin—urinary bladder cancer	0.000914	0.00173	CcSEcCtD
Alendronate—Pain—Cisplatin—urinary bladder cancer	0.000914	0.00173	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000911	0.00172	CcSEcCtD
Alendronate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000906	0.00171	CcSEcCtD
Alendronate—Dizziness—Thiotepa—urinary bladder cancer	0.000901	0.0017	CcSEcCtD
Alendronate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000899	0.0017	CcSEcCtD
Alendronate—Stomatitis—Methotrexate—urinary bladder cancer	0.000896	0.00169	CcSEcCtD
Alendronate—Urticaria—Fluorouracil—urinary bladder cancer	0.000895	0.00169	CcSEcCtD
Alendronate—Dysphagia—Doxorubicin—urinary bladder cancer	0.000893	0.00169	CcSEcCtD
Alendronate—Asthma—Doxorubicin—urinary bladder cancer	0.000893	0.00169	CcSEcCtD
Alendronate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000891	0.00168	CcSEcCtD
Alendronate—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000881	0.00166	CcSEcCtD
Alendronate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000881	0.00166	CcSEcCtD
Alendronate—Vomiting—Thiotepa—urinary bladder cancer	0.000866	0.00164	CcSEcCtD
Alendronate—Rash—Thiotepa—urinary bladder cancer	0.000859	0.00162	CcSEcCtD
Alendronate—Dermatitis—Thiotepa—urinary bladder cancer	0.000858	0.00162	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—CDH1—urinary bladder cancer	0.000856	0.0144	CbGpPWpGaD
Alendronate—Headache—Thiotepa—urinary bladder cancer	0.000854	0.00161	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000853	0.00161	CcSEcCtD
Alendronate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000845	0.0016	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00084	0.0141	CbGpPWpGaD
Alendronate—Stomatitis—Epirubicin—urinary bladder cancer	0.000839	0.00158	CcSEcCtD
Alendronate—Pain—Etoposide—urinary bladder cancer	0.000837	0.00158	CcSEcCtD
Alendronate—Constipation—Etoposide—urinary bladder cancer	0.000837	0.00158	CcSEcCtD
Alendronate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00083	0.00157	CcSEcCtD
Alendronate—Haemoglobin—Methotrexate—urinary bladder cancer	0.000829	0.00157	CcSEcCtD
Alendronate—Haemorrhage—Methotrexate—urinary bladder cancer	0.000825	0.00156	CcSEcCtD
Alendronate—Asthenia—Gemcitabine—urinary bladder cancer	0.000822	0.00155	CcSEcCtD
Alendronate—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000815	0.00154	CcSEcCtD
Alendronate—Pruritus—Gemcitabine—urinary bladder cancer	0.000811	0.00153	CcSEcCtD
Alendronate—Nausea—Thiotepa—urinary bladder cancer	0.000809	0.00153	CcSEcCtD
Alendronate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000807	0.00152	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000805	0.0135	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.0008	0.00151	CcSEcCtD
Alendronate—Pruritus—Fluorouracil—urinary bladder cancer	0.000797	0.00151	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000789	0.00149	CcSEcCtD
Alendronate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000787	0.00149	CcSEcCtD
Alendronate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000784	0.00148	CcSEcCtD
Alendronate—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00078	0.00147	CcSEcCtD
Alendronate—Urticaria—Etoposide—urinary bladder cancer	0.000778	0.00147	CcSEcCtD
Alendronate—Haemoglobin—Epirubicin—urinary bladder cancer	0.000776	0.00147	CcSEcCtD
Alendronate—Stomatitis—Doxorubicin—urinary bladder cancer	0.000776	0.00147	CcSEcCtD
Alendronate—Body temperature increased—Etoposide—urinary bladder cancer	0.000774	0.00146	CcSEcCtD
Alendronate—Abdominal pain—Etoposide—urinary bladder cancer	0.000774	0.00146	CcSEcCtD
Alendronate—Haemorrhage—Epirubicin—urinary bladder cancer	0.000772	0.00146	CcSEcCtD
Alendronate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000771	0.00146	CcSEcCtD
Alendronate—Asthenia—Cisplatin—urinary bladder cancer	0.000767	0.00145	CcSEcCtD
Alendronate—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000761	0.00144	CcSEcCtD
Alendronate—Dizziness—Fluorouracil—urinary bladder cancer	0.000745	0.00141	CcSEcCtD
Alendronate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000731	0.00138	CcSEcCtD
Alendronate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00073	0.00138	CcSEcCtD
Alendronate—Alopecia—Methotrexate—urinary bladder cancer	0.000729	0.00138	CcSEcCtD
Alendronate—Vomiting—Gemcitabine—urinary bladder cancer	0.000729	0.00138	CcSEcCtD
Alendronate—Rash—Gemcitabine—urinary bladder cancer	0.000723	0.00137	CcSEcCtD
Alendronate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000722	0.00136	CcSEcCtD
Alendronate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000721	0.00136	CcSEcCtD
Alendronate—Erythema—Methotrexate—urinary bladder cancer	0.000718	0.00136	CcSEcCtD
Alendronate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000718	0.00136	CcSEcCtD
Alendronate—Headache—Gemcitabine—urinary bladder cancer	0.000718	0.00136	CcSEcCtD
Alendronate—Vomiting—Fluorouracil—urinary bladder cancer	0.000717	0.00135	CcSEcCtD
Alendronate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000715	0.00135	CcSEcCtD
Alendronate—Rash—Fluorouracil—urinary bladder cancer	0.000711	0.00134	CcSEcCtD
Alendronate—Dermatitis—Fluorouracil—urinary bladder cancer	0.00071	0.00134	CcSEcCtD
Alendronate—Headache—Fluorouracil—urinary bladder cancer	0.000706	0.00133	CcSEcCtD
Alendronate—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000704	0.00133	CcSEcCtD
Alendronate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000704	0.00133	CcSEcCtD
Alendronate—Asthenia—Etoposide—urinary bladder cancer	0.000702	0.00133	CcSEcCtD
Alendronate—Pruritus—Etoposide—urinary bladder cancer	0.000693	0.00131	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000685	0.0115	CbGpPWpGaD
Alendronate—Alopecia—Epirubicin—urinary bladder cancer	0.000682	0.00129	CcSEcCtD
Alendronate—Nausea—Gemcitabine—urinary bladder cancer	0.000681	0.00129	CcSEcCtD
Alendronate—Vomiting—Cisplatin—urinary bladder cancer	0.000679	0.00128	CcSEcCtD
Alendronate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000676	0.00128	CcSEcCtD
Alendronate—Rash—Cisplatin—urinary bladder cancer	0.000674	0.00127	CcSEcCtD
Alendronate—Dermatitis—Cisplatin—urinary bladder cancer	0.000673	0.00127	CcSEcCtD
Alendronate—Erythema—Epirubicin—urinary bladder cancer	0.000672	0.00127	CcSEcCtD
Alendronate—Diarrhoea—Etoposide—urinary bladder cancer	0.00067	0.00127	CcSEcCtD
Alendronate—Nausea—Fluorouracil—urinary bladder cancer	0.000669	0.00126	CcSEcCtD
Alendronate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000667	0.00126	CcSEcCtD
Alendronate—Anaemia—Methotrexate—urinary bladder cancer	0.000664	0.00125	CcSEcCtD
Alendronate—Flatulence—Epirubicin—urinary bladder cancer	0.000663	0.00125	CcSEcCtD
Alendronate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000658	0.00124	CcSEcCtD
Alendronate—ATP6V1A—Disease—GSTO2—urinary bladder cancer	0.00065	0.0109	CbGpPWpGaD
Alendronate—Malaise—Methotrexate—urinary bladder cancer	0.000648	0.00122	CcSEcCtD
Alendronate—Dizziness—Etoposide—urinary bladder cancer	0.000647	0.00122	CcSEcCtD
Alendronate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000646	0.00122	CcSEcCtD
Alendronate—Vertigo—Methotrexate—urinary bladder cancer	0.000645	0.00122	CcSEcCtD
Alendronate—Nausea—Cisplatin—urinary bladder cancer	0.000635	0.0012	CcSEcCtD
Alendronate—Alopecia—Doxorubicin—urinary bladder cancer	0.000631	0.00119	CcSEcCtD
Alendronate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000624	0.00118	CcSEcCtD
Alendronate—Vomiting—Etoposide—urinary bladder cancer	0.000622	0.00118	CcSEcCtD
Alendronate—Erythema—Doxorubicin—urinary bladder cancer	0.000622	0.00118	CcSEcCtD
Alendronate—Anaemia—Epirubicin—urinary bladder cancer	0.000621	0.00117	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—MMP9—urinary bladder cancer	0.000619	0.0104	CbGpPWpGaD
Alendronate—Rash—Etoposide—urinary bladder cancer	0.000617	0.00117	CcSEcCtD
Alendronate—Dermatitis—Etoposide—urinary bladder cancer	0.000617	0.00116	CcSEcCtD
Alendronate—Headache—Etoposide—urinary bladder cancer	0.000613	0.00116	CcSEcCtD
Alendronate—Flatulence—Doxorubicin—urinary bladder cancer	0.000613	0.00116	CcSEcCtD
Alendronate—Chest pain—Methotrexate—urinary bladder cancer	0.000612	0.00116	CcSEcCtD
Alendronate—Myalgia—Methotrexate—urinary bladder cancer	0.000612	0.00116	CcSEcCtD
Alendronate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000609	0.00115	CcSEcCtD
Alendronate—Malaise—Epirubicin—urinary bladder cancer	0.000606	0.00115	CcSEcCtD
Alendronate—Discomfort—Methotrexate—urinary bladder cancer	0.000604	0.00114	CcSEcCtD
Alendronate—Vertigo—Epirubicin—urinary bladder cancer	0.000604	0.00114	CcSEcCtD
Alendronate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000598	0.00113	CcSEcCtD
Alendronate—Infection—Methotrexate—urinary bladder cancer	0.000583	0.0011	CcSEcCtD
Alendronate—Nausea—Etoposide—urinary bladder cancer	0.000581	0.0011	CcSEcCtD
Alendronate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000577	0.00109	CcSEcCtD
Alendronate—Anaemia—Doxorubicin—urinary bladder cancer	0.000575	0.00109	CcSEcCtD
Alendronate—Chest pain—Epirubicin—urinary bladder cancer	0.000572	0.00108	CcSEcCtD
Alendronate—Myalgia—Epirubicin—urinary bladder cancer	0.000572	0.00108	CcSEcCtD
Alendronate—Discomfort—Epirubicin—urinary bladder cancer	0.000566	0.00107	CcSEcCtD
Alendronate—Malaise—Doxorubicin—urinary bladder cancer	0.000561	0.00106	CcSEcCtD
Alendronate—Vertigo—Doxorubicin—urinary bladder cancer	0.000559	0.00106	CcSEcCtD
Alendronate—Infection—Epirubicin—urinary bladder cancer	0.000545	0.00103	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000534	0.00101	CcSEcCtD
Alendronate—Chest pain—Doxorubicin—urinary bladder cancer	0.00053	0.001	CcSEcCtD
Alendronate—Myalgia—Doxorubicin—urinary bladder cancer	0.00053	0.001	CcSEcCtD
Alendronate—Discomfort—Doxorubicin—urinary bladder cancer	0.000523	0.000989	CcSEcCtD
Alendronate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000516	0.000975	CcSEcCtD
Alendronate—ATP6V1A—Disease—SLC19A1—urinary bladder cancer	0.000505	0.0085	CbGpPWpGaD
Alendronate—Infection—Doxorubicin—urinary bladder cancer	0.000504	0.000953	CcSEcCtD
Alendronate—Pain—Methotrexate—urinary bladder cancer	0.000501	0.000947	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.0005	0.000944	CcSEcCtD
Alendronate—ATP6V1A—Disease—PRSS3—urinary bladder cancer	0.000493	0.00828	CbGpPWpGaD
Alendronate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000483	0.000913	CcSEcCtD
Alendronate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000483	0.000913	CcSEcCtD
Alendronate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000479	0.000906	CcSEcCtD
Alendronate—ATP6V1A—Disease—HDAC4—urinary bladder cancer	0.00047	0.0079	CbGpPWpGaD
Alendronate—Pain—Epirubicin—urinary bladder cancer	0.000469	0.000886	CcSEcCtD
Alendronate—Constipation—Epirubicin—urinary bladder cancer	0.000469	0.000886	CcSEcCtD
Alendronate—Urticaria—Methotrexate—urinary bladder cancer	0.000466	0.00088	CcSEcCtD
Alendronate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000464	0.000876	CcSEcCtD
Alendronate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000464	0.000876	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000463	0.00778	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000463	0.000874	CcSEcCtD
Alendronate—FDPS—Metabolism—GSTZ1—urinary bladder cancer	0.000459	0.00772	CbGpPWpGaD
Alendronate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000452	0.000854	CcSEcCtD
Alendronate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000449	0.000848	CcSEcCtD
Alendronate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000447	0.000844	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—KRAS—urinary bladder cancer	0.000446	0.00749	CbGpPWpGaD
Alendronate—Urticaria—Epirubicin—urinary bladder cancer	0.000436	0.000824	CcSEcCtD
Alendronate—FDPS—Metabolism—GSTO2—urinary bladder cancer	0.000435	0.00732	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NAT1—urinary bladder cancer	0.000435	0.00732	CbGpPWpGaD
Alendronate—Pain—Doxorubicin—urinary bladder cancer	0.000434	0.00082	CcSEcCtD
Alendronate—Constipation—Doxorubicin—urinary bladder cancer	0.000434	0.00082	CcSEcCtD
Alendronate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000434	0.000819	CcSEcCtD
Alendronate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000434	0.000819	CcSEcCtD
Alendronate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000432	0.000816	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000428	0.0072	CbGpPWpGaD
Alendronate—Asthenia—Methotrexate—urinary bladder cancer	0.000421	0.000795	CcSEcCtD
Alendronate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000418	0.00079	CcSEcCtD
Alendronate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000415	0.000784	CcSEcCtD
Alendronate—Pruritus—Methotrexate—urinary bladder cancer	0.000415	0.000784	CcSEcCtD
Alendronate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000404	0.000764	CcSEcCtD
Alendronate—Urticaria—Doxorubicin—urinary bladder cancer	0.000403	0.000762	CcSEcCtD
Alendronate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000401	0.000758	CcSEcCtD
Alendronate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000401	0.000758	CcSEcCtD
Alendronate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000401	0.000758	CcSEcCtD
Alendronate—FDPS—Metabolism—UGT2B7—urinary bladder cancer	0.000398	0.00669	CbGpPWpGaD
Alendronate—Asthenia—Epirubicin—urinary bladder cancer	0.000394	0.000744	CcSEcCtD
Alendronate—Pruritus—Epirubicin—urinary bladder cancer	0.000388	0.000733	CcSEcCtD
Alendronate—Dizziness—Methotrexate—urinary bladder cancer	0.000388	0.000733	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—HRAS—urinary bladder cancer	0.000379	0.00637	CbGpPWpGaD
Alendronate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000375	0.000709	CcSEcCtD
Alendronate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000374	0.000707	CcSEcCtD
Alendronate—ATP6V1A—Disease—LIG1—urinary bladder cancer	0.000373	0.00628	CbGpPWpGaD
Alendronate—Vomiting—Methotrexate—urinary bladder cancer	0.000373	0.000704	CcSEcCtD
Alendronate—Rash—Methotrexate—urinary bladder cancer	0.00037	0.000698	CcSEcCtD
Alendronate—Dermatitis—Methotrexate—urinary bladder cancer	0.000369	0.000698	CcSEcCtD
Alendronate—Headache—Methotrexate—urinary bladder cancer	0.000367	0.000694	CcSEcCtD
Alendronate—Asthenia—Doxorubicin—urinary bladder cancer	0.000364	0.000688	CcSEcCtD
Alendronate—Dizziness—Epirubicin—urinary bladder cancer	0.000363	0.000686	CcSEcCtD
Alendronate—Pruritus—Doxorubicin—urinary bladder cancer	0.000359	0.000679	CcSEcCtD
Alendronate—FDPS—Metabolism—CYP4B1—urinary bladder cancer	0.000358	0.00603	CbGpPWpGaD
Alendronate—Vomiting—Epirubicin—urinary bladder cancer	0.000349	0.000659	CcSEcCtD
Alendronate—Nausea—Methotrexate—urinary bladder cancer	0.000348	0.000658	CcSEcCtD
Alendronate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000347	0.000656	CcSEcCtD
Alendronate—Rash—Epirubicin—urinary bladder cancer	0.000346	0.000654	CcSEcCtD
Alendronate—Dermatitis—Epirubicin—urinary bladder cancer	0.000346	0.000653	CcSEcCtD
Alendronate—Headache—Epirubicin—urinary bladder cancer	0.000344	0.000649	CcSEcCtD
Alendronate—FDPS—Metabolism—SLC19A1—urinary bladder cancer	0.000338	0.00569	CbGpPWpGaD
Alendronate—Dizziness—Doxorubicin—urinary bladder cancer	0.000336	0.000634	CcSEcCtD
Alendronate—FDPS—Metabolism—PRSS3—urinary bladder cancer	0.00033	0.00555	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000329	0.00553	CbGpPWpGaD
Alendronate—Nausea—Epirubicin—urinary bladder cancer	0.000326	0.000616	CcSEcCtD
Alendronate—Vomiting—Doxorubicin—urinary bladder cancer	0.000323	0.00061	CcSEcCtD
Alendronate—Rash—Doxorubicin—urinary bladder cancer	0.00032	0.000605	CcSEcCtD
Alendronate—Dermatitis—Doxorubicin—urinary bladder cancer	0.00032	0.000604	CcSEcCtD
Alendronate—Headache—Doxorubicin—urinary bladder cancer	0.000318	0.000601	CcSEcCtD
Alendronate—Nausea—Doxorubicin—urinary bladder cancer	0.000302	0.00057	CcSEcCtD
Alendronate—ATP6V1A—Disease—ENO2—urinary bladder cancer	0.000285	0.00479	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GLI1—urinary bladder cancer	0.000276	0.00464	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—RBX1—urinary bladder cancer	0.00027	0.00454	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000264	0.00445	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TYMP—urinary bladder cancer	0.000264	0.00443	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000253	0.00426	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—JAG1—urinary bladder cancer	0.000242	0.00406	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NAT2—urinary bladder cancer	0.000238	0.00401	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000217	0.00364	CbGpPWpGaD
Alendronate—FDPS—Metabolism—RRM2—urinary bladder cancer	0.000206	0.00346	CbGpPWpGaD
Alendronate—FDPS—Metabolism—HPGDS—urinary bladder cancer	0.000191	0.00321	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ENO2—urinary bladder cancer	0.000191	0.00321	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.00019	0.00319	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—RBX1—urinary bladder cancer	0.000189	0.00318	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTT1—urinary bladder cancer	0.000185	0.00311	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000182	0.00306	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TSC1—urinary bladder cancer	0.000178	0.00299	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NCOR1—urinary bladder cancer	0.000176	0.00296	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—JAG1—urinary bladder cancer	0.000169	0.00284	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ERCC2—urinary bladder cancer	0.000165	0.00278	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTHFR—urinary bladder cancer	0.000155	0.00261	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TERT—urinary bladder cancer	0.000155	0.00261	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NQO1—urinary bladder cancer	0.000154	0.00258	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000149	0.00251	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—FGFR3—urinary bladder cancer	0.000142	0.00239	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—S100B—urinary bladder cancer	0.000137	0.0023	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.00013	0.00219	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTP1—urinary bladder cancer	0.000128	0.00216	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000124	0.00208	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NCOR1—urinary bladder cancer	0.000123	0.00207	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CREBBP—urinary bladder cancer	0.000121	0.00204	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TYMS—urinary bladder cancer	0.000119	0.002	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NCOR1—urinary bladder cancer	0.000118	0.00198	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTM1—urinary bladder cancer	0.000118	0.00198	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GPX1—urinary bladder cancer	0.000113	0.0019	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ERCC2—urinary bladder cancer	0.000111	0.00186	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—RHOA—urinary bladder cancer	0.00011	0.00184	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TERT—urinary bladder cancer	0.000109	0.00183	CbGpPWpGaD
Alendronate—FDPS—Metabolism—MTHFR—urinary bladder cancer	0.000104	0.00175	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ERBB2—urinary bladder cancer	0.000101	0.00171	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—FGFR3—urinary bladder cancer	9.96e-05	0.00168	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTGS2—urinary bladder cancer	9.92e-05	0.00167	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ESR1—urinary bladder cancer	9.68e-05	0.00163	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1A—urinary bladder cancer	8.67e-05	0.00146	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTEN—urinary bladder cancer	8.65e-05	0.00145	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CREBBP—urinary bladder cancer	8.48e-05	0.00143	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PPARG—urinary bladder cancer	8.44e-05	0.00142	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IGF1—urinary bladder cancer	8.37e-05	0.00141	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EP300—urinary bladder cancer	8.25e-05	0.00139	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CREBBP—urinary bladder cancer	8.11e-05	0.00136	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—SRC—urinary bladder cancer	8.02e-05	0.00135	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—RHOA—urinary bladder cancer	7.67e-05	0.00129	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MYC—urinary bladder cancer	7.19e-05	0.00121	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.1e-05	0.00119	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—EGFR—urinary bladder cancer	7.03e-05	0.00118	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CXCL8—urinary bladder cancer	6.73e-05	0.00113	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KRAS—urinary bladder cancer	6.64e-05	0.00112	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS2—urinary bladder cancer	6.64e-05	0.00112	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL2—urinary bladder cancer	6.44e-05	0.00108	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—urinary bladder cancer	6.27e-05	0.00106	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MMP9—urinary bladder cancer	6.09e-05	0.00102	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.07e-05	0.00102	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PTEN—urinary bladder cancer	6.06e-05	0.00102	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTEN—urinary bladder cancer	5.79e-05	0.000974	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EP300—urinary bladder cancer	5.78e-05	0.000971	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HRAS—urinary bladder cancer	5.64e-05	0.000949	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SRC—urinary bladder cancer	5.62e-05	0.000944	CbGpPWpGaD
Alendronate—FDPS—Metabolism—EP300—urinary bladder cancer	5.52e-05	0.000929	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MYC—urinary bladder cancer	5.03e-05	0.000846	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—EGFR—urinary bladder cancer	4.92e-05	0.000828	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KRAS—urinary bladder cancer	4.65e-05	0.000782	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—urinary bladder cancer	4.13e-05	0.000695	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HRAS—urinary bladder cancer	3.95e-05	0.000665	CbGpPWpGaD
